PURPOSE: To evaluate the efficacy and safety of mitomycin C (MMC) 0.02% in inhibiting haze formation after excimer laser photorefractive keratectomy (PRK) for residual myopia following radial keratotomy (RK). METHODS: A prospective, nonrandomized, noncomparative interventional case series was conducted of 22 eyes (14 patients) with residual myopia after RK performed at a single institution. All eyes were treated with PRK and a single intraoperative topical application of MMC 0.02% solution for 2 minutes using a soaked cellulose sponge placed over the ablated area. Refraction, uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), and slit-lamp evidence of corneal opacity (haze) were evaluated over 12 months. RESULTS: Twelve months postoperatively, 3 eyes showed grade 1 haze, and 2 eyes showed grade 0.5 haze. Twelve months postoperatively, 2 (9%) eyes had UCVA ≥20/20. No eye before and 17 (77%) eyes after treatment had UCVA 3*20/40, and no eye before and 9 eyes (40.9%) after treatment had UCVA 2=20/25. Best spectacle-corrected visual acuity was 2=20/40 in all (100%) eyes and 21 (95%) eyes before and after treatment, respectively, and 2=20/25 in 12 (54.5%) eyes before and after treatment. One (4.5%) eye lost 1 line of BSCVA. Mean spherical equivalent refraction achieved was -0.18 diopters (D) (range: -0.75 to +0.50 D) compared to -2.72 D (range: -1.50 to -4.00 D) before treatment. Twelve months after treatment, 19 (85.5%) eyes had a refractive outcome within ±0.50 D. CONCLUSIONS: A single intraoperative application of MMC 0.02% for 2 minutes appears to be effective in preventing subepithelial haze after PRK for residual myopia in patients with undercorrection or regression following RK. [J Refract Surg. 2007;23:226-232.]

No abstract

Purpose: To evaluate the clinical outcome(s) and complication(s) of subcon junctival bevacizumab treatment in patients with recurrent pterygium. Methods: This prospective case series included patients who had undergone pterygium surgery and were diagnosed with recurrent pterygium. All patients received one subconjunctival injection of 0.5 mL of bevacizumab (2.5 mg/0.1 mL). The main outcome was the change in size and clinical appearance. The clinical appearance of the pterygium was graded according to Tan and colleagues. The horizontal size of the pterygium (from limbus to apex) was recorded from baseline to 2 months after injection. Treatmentrelated complications and adverse events were reported. Results: We included 36 eyes of 36 patients (18 males) with a mean age of 58.75 ± 10.98 years. Totally, 30.6% patients developed recurrent pterygium in both eyes (only the worst eye was treated), with 47.2% developing it in the left eye and 22.2% in the right eye. More than half the patients (58.3%) had a family history of pterygium. There was a significant difference in the size of pterygium at different intervals (P<0.05). Approximately twothirds (66.7%) of patients pre sented with hyposphagma on the 2 nd day after subconjunctival application; this value decreased to 30.6% by day 7 and to 0% at 1 month. Most patients (69.4%) ex hibited amelioration of irritative symptoms within 2 days, 88.9% after 7 days, and 97.2% after 1 month. Conclusions: Subconjunctival bevacizumab injection is useful for the manage ment of patients with recurrent pterygium, with no significant local or systemic adverse effects.